MedCity News June 22, 2025
Caris Life Sciences applies AI and machine learning to patient samples to detect cancer and as a companion diagnostic guiding the use of targeted cancer therapies. As a commercial-stage company, Caris’s upsized public markets debut is an outlier amid the continuing IPO freeze for clinical-stage biotechs developing new drugs.
Cancer treatment continues to evolve with the identification of targets and genetic signatures that guide development of therapies addressing those disease-defining markers. Caris Life Sciences’ artificial intelligence-driven offerings diagnose cancer and help oncologists determine which targeted therapies to use. The company has launched two key offerings in the past 18 months. Now it has $494 million in IPO cash to support its precision medicine plans in the present, and to potentially...
Today's Sponsors
Today's Sponsor